ArticleThe Journal of biological chemistry2026
Reversible homodimerization of a small leucine-rich proteoglycan PRELP modulates the interactions with TGFβ1 and IGFI-R.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small leucine-rich proteoglycans (SLRPs) are responsible for various biological functions via their multiple interactions with various proteins. Although some SLRPs form homodimers, it remains unclear how homodimerization affects the molecular functions of SLRPs. Herein, we report the molecular basis and functional significance of homodimerization of proline/arginine-rich end leucine-rich repeat protein (PRELP), which is a member of SLRP family. We used biophysical techniques to validate the premise that PRELP forms a reversible homodimer in a concentration-dependent manner. Because the spatial aggregation propensity calculation indicated that the concave surface of the leucine-rich repeat domain of PRELP is highly hydrophobic, we speculated that this hydrophobicity predominantly drives PRELP homodimerization. To address this hypothesis, we replaced several amino acid residues that showed high spatial aggregation propensity values with charged residues identified by the Rosetta energy calculation, which resulted in disruption of PRELP homodimerization. Molecular dynamics simulation further verified the molecular basis of the monomerizing mutation as well as an unexpected dimerizing mutation. To demonstrate the influence of reversible homodimerization on PRELP interactions, we conducted interaction analysis using the designed PRELP mutants. We found that the monomerizing mutation of PRELP enhanced interactions with transforming growth factor β1 and insulin-like growth factor I receptor, suggesting that the functions of PRELP that rely on these interactions are moderated via reversible homodimerization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.